TP53 密码子 72 多态性与霍奇金和非霍奇金淋巴瘤的风险或预后无关。
No association between the TP53 codon 72 polymorphism and risk or prognosis of Hodgkin and non-Hodgkin lymphoma.
机构信息
1st Department of Medicine, 1st Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic.
出版信息
Leuk Res. 2011 Aug;35(8):1117-9. doi: 10.1016/j.leukres.2011.04.001. Epub 2011 May 5.
The role of the TP53 gene's R72P polymorphism in non-Hodgkin lymphoma (NHL) has been analyzed in several studies but it has not been studied in Hodgkin lymphoma (HL). We have evaluated the role of R72P in 340 NHL and 298 HL patients. There was no difference in the R72P frequency between analyzed lymphoma cases and 749 controls. We found no association of R72P with the risk of NHL and HL development [OR(ArgPro/ProPro)=0.9 (95% CI 0.7-1.2) and 1.2 (95% CI 0.9-1.5), respectively] or with survival. Our results support the evidence that R72P is not a prognostic factor in Caucasian NHL patients, and they indicate its irrelevance for HL development or prognosis.
TP53 基因的 R72P 多态性在非霍奇金淋巴瘤 (NHL) 中的作用已在多项研究中进行了分析，但在霍奇金淋巴瘤 (HL) 中尚未进行研究。我们评估了 340 例 NHL 和 298 例 HL 患者中 R72P 的作用。在分析的淋巴瘤病例和 749 名对照者之间，R72P 的频率没有差异。我们没有发现 R72P 与 NHL 和 HL 发展的风险相关[比值比（ArgPro/ProPro）=0.9（95%置信区间 0.7-1.2）和 1.2（95%置信区间 0.9-1.5）]，也与生存无关。我们的结果支持 R72P 不是白种人 NHL 患者预后因素的证据，并且表明其与 HL 的发生或预后无关。
Zotero 插件